ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : Industry : Genentech


Include trials that are no longer recruiting patients.

11 studies were found.
1.RecruitingAvastin With or Without Erlotinib for Treatment of Metastatic Renal Cell Carcinoma
Condition: Renal Cell Cancer
2.RecruitingErlotinib in Patients with Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small Cell Lung
3.RecruitingEvaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer
Condition: Breast Cancer
4.RecruitingAn Evaluation of the Safety and Efficacy of Ranibizumab in Patients with Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
5.RecruitingRhVEGF (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers
Condition: Diabetic Foot
6.RecruitingRituximab/Fludarabine/Cyclophosphamide (FCR) versus Fludarabine/Cyclophosphamide (FC) Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
7.RecruitingSafety and Efficacy Study of Nutropin AQ to Treat Growth Restriction in Children with Cystic Fibrosis
Condition: Cystic Fibrosis
8.RecruitingSafety and Efficacy Study of Rituximab Compared with Placebo in Adults with Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
9.RecruitingA Safety and Efficacy Study of Xolair in Peanut Allergy
Condition: Allergy
10.RecruitingA Safety Study of Escalating Doses of PRO70769 for Subjects with Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate
Condition: Rheumatoid Arthritis
11.RecruitingStudy to evaluate the safety and effect of pertuzumab in patients with advanced non-small cell lung cancer, which has progressed after prior chemotherapy
Condition: Non-small cell lung cancer

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act